Skip to main content


Drug Target Review: Synthetic biology is ready for the therapeutic limelight

By Featured News, News

After initially serving as a proving ground for integrating forward engineering principles into living cells, synthetic biology is making waves across diverse therapeutic areas. In this article, Dr. Dan Mandell, Co-Founder and CEO of GRO Biosciences, explains how the field is reshaping our understanding of the limits of cell- and molecular-based medicines.

Read More

One year, 1 lab, 16 spinouts

By News

In the early 2000s, Jay Shendure was a graduate student in George Church’s lab at Harvard University. Back then, he says, there was “hardly an inkling” that the lab would become a hotbed of startup activity.

Read More